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Abstract
This study sought to determine whether an increase in resistance of Rhodococcus equi to the antibiotics rifampin and erythromycin 
occurred over a 10-year period. This was carried out by the use of E test strips for rifampin and erythromycin to determine the MIC 
(minimum inhibitory concentration) values of Rhodococcus equi to this combination of antibiotics.
The findings of this study indicated that there was an increase in resistance of Rhodococcus equi to rifampin and erythromycin over the 
10-year period. The MIC for rifampin increased from 0.081µg/ml in 1996 to 0.187µg/ml in 2006 and from 0.258µg/ml for erythromycin 
during the years prior to 2000 to 0.583µg/ml in 2006. 
This finding suggests that there may be a problem in the treatment of Rhodococcus equi infections in foals in the future, particularly as the 
number of drugs available for treatment of Rhodococcus equi infection is limited because of the intracellular capabilities of this bacterium. 
Antibiotics used in its treatment have to be able to penetrate the polysaccharide cell wall of Rhodococcus equi as well as the alveolar 
macrophages in which the bacterium is capable of surviving. 
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Introduction
Rhodococcus equi is a facultative, intracellular, non-
motile, non-spore-forming, Gram-positive cocco-bacillus 
(Kedlaya and Ing, 2007). The bacterium has the name 
Rhodococcus because of its ability to form a red (salmon 
coloured) pigment. Rhodococcus equi was previously 
called Corynebacterium equi and currently is grouped 
with the aerobic actinomycetes (Kedlaya and Ing, 2007). 
Rhodococcus equi organisms most often induce chronic 
bronchopneumonia in young foals (Bertone et al., 1998). 
Rhodococcus equi can also cause other clinical conditions 
such as intestinal disease, non-specific synovitis and 
sporadic abscesses, but these syndromes are not as common 
as the pneumonic syndrome. Rhodococcus equi-associated 
bronchopneumonia of young foals was originally identified 
in 1923 (Bertone et al., 1998). Rhodococcus equi is largely 
a soil organism with simple growth requirements, which 
appear to be met perfectly by herbivore manure and 
summer temperatures in temperate climates (Prescott, 
1991). Farms used for foal breeding over many years may 
thus become particularly dangerous for foals (Prescott, 
1987).
Rhodococcus equi, although not the most common cause 
of pneumonia in foals from one to five months of age, 
has significant economic consequences due to mortality, 
prolonged treatment, surveillance programmes for early 
detection and relatively expensive prophylactic strategies 
(Prescott and Baggott, 1993). The susceptibility of foals 
under six months of age to respiratory infections may be 
due to a number of factors, including: immunodeficiency; 
overcrowding; heavy parasite burden; poor nutritional 
status; and heat stress (Prescott, 1993). There may also be 
a genetic basis for foal susceptibility to Rhodococcus equi 
infection based on the type of transferrin, an iron-binding 
protein that has bacteriostatic properties, in the blood 
(Mousel et al., 2003). Also, only certain types of Rhodococcus 
equi are pathogenic: those that contain virulence-associated 
protein A -Vap A. (Giguere et al., 1999).  Rhodococcus 
equi pneumonia can progress to severe and extensive lung 
involvement prior to the development of clear clinical 
signs (Bertone et al., 1998).  Of the many bacterial and viral 
agents that can cause foal pneumonia, Rhodococcus equi 
is one of the most difficult to treat but has been shown 
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to leave no residual lung damage following recovery 
(Ainsworth et	al., 1993) and have no lasting affect on future 
racing performance (Ainsworth et	al., 1998).
Rhodococcus	equi was previously thought to be exclusively 
an equine pathogen, but in recent years Rhodococcus	equi 
infection is occurring with increasing frequency in humans 
(Prescott, 1991).  Infection in a human was first reported 
in 1967 in a 29-year-old man with plasma cell hepatitis 
receiving immunosuppressant medications (Kedlaya and 
Ing, 2007). It is found exclusively in immunocompromised 
individuals, such as those with AIDS, small cell carcinoma 
of the lung, malignant lymphoma, or recipients of kidney 
or bone marrow transplants (Todar, 2002).
The organism is particularly susceptible to erythromycin 
and clindamycin; the aminoglycosides, amikacin, 
gentamycin, neomycin and tobromycin, rifampin and 
vancomycin (Prescott, 1991). It is moderately susceptible 
to penicillin G, ampicillin and tetracyclines, and is usually 
moderately susceptible or resistant to first and second 
generation cephalosporins (Prescott, 1991).
As determined by FIC (fractional inhibitory 
concentration) indices, four combinations were synergistic: 
rifampin–erythromycin, rifampin–minocycline, 
erythromycin–minocycline and imipenem–amikacin 
(Nordmam and Roncon, 1992). Standard therapy involves 
the use of a combination of erythromycin and rifampin 
(Bertone et	al., 1998). In order to treat Rhodococcus	equi 
infection successfully, it is necessary to select an antibiotic 
which is not only effective against the organism in	vitro, 
but which also has good distribution and activity in the 
lungs, with the ability to penetrate and sterilise caseous 
abscess cavities and to kill Rhodococcus	equi organisms 
within neutrophils and macrophages (Hillidge, 1987). By 
using the combination of erythromycin and rifampin, not 
only are these drugs highly effective in	vitro, they also 
penetrate macrophages well and have been shown to have 
additive and often synergistic activity in	vitro (Prescott, 
1991). 
Erythromycin is a member of the macrolide group of 
antibiotics; it selectively inhibits protein synthesis in a 
broad range of bacteria by binding to the 50S subunit 
of the bacterial ribosome (Todar, 2002). Resistance to 
erythromycin can occur by methylation of different bases 
within the same region of the 23S rRNA (Todar, 2002). 
Erythromycin also blocks translation. 
Rifampin is the most important synthetically modified 
member of the family of the rifamycins, antibiotic 
products of Streptomyces	mediterranei (Prescott and 
Baggot, 1993). It is always combined with other antibiotics 
because of the ready development of resistance to the 
drug (Prescott and Baggot, 1993). Rifampin has the 
unique action among antibiotics of inhibiting RNA 
polymerase, the enzyme that catalyses the transcription 
of DNA to RNA (Prescott and Baggot, 1993). Rifampin 
binds to the beta subunit of the enzyme and causes 
abortive initiation of RNA synthesis (Prescott and Baggot, 
1993). Rifampin is a bactericidal antibiotic with a wide 
spectrum of antimicrobial activity including activity 
against Gram-positive bacteria and anaerobes and some 
antiviral and antifungal activity (Prescott and Baggot, 
1993). An attractive feature of rifampin is its ability to kill 
intracellular bacteria (Prescott and Baggot, 1993).
Dosages for the erythromycin–rifampin combination 
range from 5-10 mg/kg orally one- to two-times daily for 
rifampin to 10-37.5 mg/kg orally two- to four-times daily 
for erythromycin (Bertone et	al.,	1998). 
Figure 1: Rhodococcus equi organisms most often induce chronic bronchopneumonia 
in young foals.
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The length of treatment depends on the clinical 
response, the return of the complete blood count and 
fibrinogen concentrations to normal and the resolution of 
radiographic and ultrasonographic abnormalities (Bertone 
et	al.,	1998). Treatment can last anything from 30 to 60 
days, depending on the recovery of the foal. 
Although the combination of rifampin and erythromycin 
has been used in the treatment of R.	equi infection 
of foals for many years, adverse effects to treatment 
can occur, including hyperthermia, tachypnoea and, 
in rare circumstances, severe diarrhoea. In addition, 
occasional reports of resistance of R.	equi to rifampin and 
erythromycin  have been published over the last number 
of years (Kenney et	al., 1994; Takai et	al., 1997; Fines et	al., 
2001).
This study sought to determine whether an increase in 
resistance of Rhodococcus	equi to the antibiotics rifampin 
and erythromycin occurred over a 10-year period.
Materials and methods
Ninety-four	Rhodococcus	equi isolates, each isolated 
from clinical cases of Rhodococcus	equi pneumonia over 
a period of 10 years (1996-2006), were stored in cooked 
meat medium at -80°C. The isolates of Rhodococcus	equi 
were analysed for their MIC values to rifampin and 
erythromycin over a 10-year period using E test strips 
(PDM Epsilometer; AB Biodisk, Solna, Sweden) of each 
of the two antibiotics. The range of the strips used was 
0.002-32µg/ml for rifampin and 0.016-256µg/ml for 
erythromycin. The zones of inhibition showed by each 
of the isolates of Rhodococcus	equi were clear and easily 
readable. ATCC (American Type Culture Collection) 
control strains were used throughout the study. These 
showed sensitivity at a low concentration.
Results
A total of 94 samples of Rhodococcus	equi were analysed 
for their MIC values to rifampin and erythromycin over 
a 10-year period using E test strips of each of the two 
antibiotics. The samples were grouped according to the 
year in which they were detected and isolated within the 
Irish Equine Centre. The range of each of the antibiotic 
strips was 0.002-32µg/ml for rifampin and 0.016-256µg/ml 
for erythromycin.
Table 1: Means and ranges of the MIC concentration of Rhodococcus	equi to rifampin 
and erythromycin for each year (µg/ml)
Year of sample 
(No. of samples 
tested)
Rifampin (range) Erythromycin (range)
2006 (12) 0.187 (0.12 – 1.00) 0.583 (0.50 – 0.75)
2005 (10) 0.181 (0.12 – 0.64) 0.496 (0.25 – 0.75)
2004 (10) 0.142 (0.12 – 0.25) 0.333 (0.25 – 0.50)
2003 (10) 0.137 (0.03 – 0.25) 0.348 (0.25 – 0.50)
2002 (11) 0.132 (0.03 – 0.25) 0.400 (0.25 – 0.38)
2001 (11) 0.125 (0.12 – 0.12) 0.265 (0.12 – 0.38)
2000 (10) 0.114 (0.04 – 0.19) 0.233 (0.19 – 0.38)
Pre-2000 (20) 0.081 (0.03 – 0.12) 0.258 (0.12 – 0.38)
As can be seen in Table 1, it is clear that there was a 
marked increase in the MIC concentration of Rhodococcus	
equi to the antibiotic rifampin. This is shown as an increase 
of the MIC from 0.081µg/ml pre-2000 to 0.187 µg/ml in 
2006. This is a major increase in MIC concentration for 
any bacterium, especially Rhodococcus	equi, because of 
the difficulties in its treatment. There is also a notable 
increase in the MIC concentration of Rhodococcus	equi 
to erythromycin. This increase is not as extreme as for 
rifampin but its increase nevertheless is noteworthy; it 
increased from 0.258µg/ml from pre-2000 to 0.583µg/ml in 
2006. 
Discussion
The MIC concentrations of rifampin to Rhodococcus	equi 
increased from 0.081µg/ml pre-2000 to 0.187µg/ml in 
2006. This is a marked increase in MIC concentration for 
any bacterial pathogen, including Rhodococcus	equi. If the 
trend of increasing resistance continues at the same rate, 
the bacterium may soon be completely resistant to this 
antibiotic and new methods of treatment may have to be 
used. Low levels of resistance are 2-8µg/ml and high levels 
of resistance are >128µg/ml (Fines et	al., 2001).  
The MIC concentrations of erythromycin to Rhodococcus	
equi increased from 0.258µg/ml pre-2000 to 0.583µg/ml in 
2006. This is also a large increase in MIC concentration 
representing an increase of 0.238µg/ml over a 10-year 
period. No resistant strains or samples of Rhodococcus	equi 
to erythromycin were detected during this experiment 
and all of the samples were within the range reported by 
Prescott (1991). There is, however, a steadily increasing 
trend of resistance occurring in Rhodococcus	equi to 
erythromycin and this increase may cause serious future 
problems in the treatment of Rhodococcus	equi foal 
pneumonia. There is also evidence of resistance in the area 
of human medicine to these antibiotics (Asoh et	al., 2003).
The consequence of these findings is that there is an 
inevitable resistance occurring in Rhodococcus	equi to 
rifampin and erythromycin and that, in the future, 
these antibiotics may be less effective in the treatment 
of foal pneumonia caused by Rhodococcus	equi. Because 
of this, the antibiotics azithromycin and clarithromycin 
have been proposed as alternatives to erythromycin and 
rifampin for the treatment of Rhodococcus	equi infections 
in foals. They are more chemically stable, have a greater 
bioavailability and achieve higher concentrations in 
phagocytic cells and tissues than erythromycin (Jacks 
et	al., 2003).  Also, persistence of high concentrations of 
azithromycin in bronchoalveolar cells after discontinuation 
of administration suggests that a shorter dosage regime may 
be applied (Jacks et	al., 2001).
Conclusion
The overall conclusion is that there is an increase 
in resistance occurring in Rhodococcus	equi to the 
antibiotics commonly used in its treatment; rifampin 
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and erythromycin. MIC concentrations of each of these 
antibiotics to the bacterium were determined over a 
10-year period and a steady increase recorded for both 
antimicrobial agents.
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